Olverembatinib tablets | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Medicine type: Chemical medicine
Therapeutic area: Oncology
Indications recorded in the public source: For adults with chronic-phase CML resistant and/or intolerant to first- and second-generation TKIs. Also for adults with chronic- or accelerated-phase CML resistant to any TKI and with a T315I mutation confirmed using a fully validated test. Conditional approval was based on response rates in a single-arm trial: major cytogenetic response in chronic phase and complete hematologic response in accelerated phase.
Indication source and scope: Source date(s): 2024. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
Prescribing-information limitations: Complete official prescribing information obtained. Mainland China label.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Restricted to: (1) adults with chronic-phase CML resistant and/or intolerant to first- and second-generation TKIs; or (2) adults with T315I-mutated chronic- or accelerated-phase CML.
Insurance period: 2025-01-01 to 2026-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions